drugset / Trial / NCT02100969
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).
Timeline
- Start
- 2015-05
- Primary completion
- 2017-11
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | — | Subcutaneous |